General
Showing 2177–2192 of 2231 results
-
Article: Tumour markers in metastatic colorectal cancer: clinical implications for treatment with targeted therapy
€3.03 Only for registered clients -
Article: Tumour mutational burden: a review
€3.03 Only for registered clients -
Article: Tyrosine kinase inhibitor discontinuation in patients with chronic myelogenous leukaemia: A retrospective study and review of the literature
€3.03 Only for registered clients -
Article: Unexpected extensive bone marrow hemophagocytosis in a post-allogeneic hematopoietic stem cell transplantation patient
€3.03 Only for registered clients -
Article: Unravelling the biology of juvenile myelomonocytic leukaemia using transcriptomics
€3.03 Only for registered clients -
Article: Unravelling the immunotherapeutic potential of CD70 as a target in solid malignancies
€3.03 Only for registered clients -
Article: Update in immune checkpoint inhibitors in non small cell lung cancer
€3.03 Only for registered clients -
Article: Update in prostate cancer 2019
€3.03 Only for registered clients -
Article: Update of the Belgian guidelines for HER2 testing in breast cancer
€3.03 Only for registered clients -
Article: Update on cancer in pregnancy
€3.03 Only for registered clients -
Article: Update on the initial therapy of multiple myeloma
€3.03 Only for registered clients -
Article: Update on therapy of relapsed and refractory multiple myeloma
€3.03 Only for registered clients -
Article: Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia anno 2016
€3.03 Only for registered clients -
Article: Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström macroglobulinemia anno 2018
€3.03 Only for registered clients -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Only for registered clients -
Article: Updated results of the TAGS trial reinforce the clinical benefit and safety of TAS-102 in patients with advanced gastric cancer
€3.03 Only for registered clients